NCT06305286
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
Phase: Phase 1/2
Role: Collaborator
Start: Mar 4, 2024
Completion: Mar 31, 2029